Thomas Reed - Precigen Founder Officer
| PGEN Stock | USD 4.93 0.19 4.01% |
Insider
Thomas Reed is Founder Officer of Precigen
| Age | 58 |
| Address | 20374 Seneca Meadows Parkway, Germantown, MD, United States, 20876 |
| Phone | 301 556 9900 |
| Web | https://precigen.com |
Precigen Management Efficiency
The company has return on total asset (ROA) of (0.6744) % which means that it has lost $0.6744 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.6803) %, meaning that it created substantial loss on money invested by shareholders. Precigen's management efficiency ratios could be used to measure how well Precigen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 17th of February 2026, Return On Tangible Assets is likely to grow to -1.13. In addition to that, Return On Capital Employed is likely to grow to -1.19. At this time, Precigen's Total Current Assets are very stable compared to the past year. As of the 17th of February 2026, Other Assets is likely to grow to about 82.6 M, while Total Assets are likely to drop about 124.2 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Alexis AM | Relay Therapeutics | 53 | |
| Justin Klee | Amylyx Pharmaceuticals | 35 | |
| HansGeorg Rammensee | Immatics NV | N/A | |
| Joshua Cohen | Amylyx Pharmaceuticals | 34 | |
| MS MD | Oric Pharmaceuticals | 59 | |
| Arnd MBA | Immatics NV | 59 | |
| Andy Porter | Relay Therapeutics | N/A | |
| MD LAc | Nektar Therapeutics | 60 | |
| Anja BSc | Immatics NV | N/A | |
| Mark Murcko | Relay Therapeutics | 64 | |
| Weidong Zhong | Terns Pharmaceuticals | 58 | |
| MA MBA | Relay Therapeutics | 48 | |
| BA BA | Oric Pharmaceuticals | 63 | |
| Steffen Walter | Immatics NV | 50 | |
| Harpreet Singh | Immatics NV | 52 | |
| PHR MBA | Immatics NV | N/A | |
| Sridhar Vaddeboina | Wave Life Sciences | N/A | |
| Kyle CFA | Wave Life Sciences | 55 | |
| Esq JD | Oric Pharmaceuticals | 49 | |
| Jonathan Rosin | Wave Life Sciences | N/A | |
| Carsten MD | Immatics NV | 59 | |
Management Performance
| Return On Equity | -6.68 | ||||
| Return On Asset | -0.67 |
Precigen Leadership Team
Elected by the shareholders, the Precigen's board of directors comprises two types of representatives: Precigen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Precigen. The board's role is to monitor Precigen's management team and ensure that shareholders' interests are well served. Precigen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Precigen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mr JD, Chief Secretary | ||
| Rob Russell, VP Resources | ||
| Phil Tennant, Chief Officer | ||
| Donald Lehr, Chief Secretary | ||
| Rutul Shah, Chief Officer | ||
| Jeffrey Perez, Senior Affairs | ||
| Randal JD, Executive Chairman | ||
| Jeffrey JD, Senior Affairs | ||
| Helen MPH, CEO President | ||
| Steven Harasym, VP Relations | ||
| Douglas Brough, Senior Research | ||
| David Witte, Chief LLC | ||
| Helen Sabzevari, CEO President | ||
| Harry Thomasian, Chief Officer | ||
| Bryan Butman, Senior CMC | ||
| Marie Rossi, Vice Communications | ||
| Thomas Reed, Founder Officer | ||
| Amy Lankford, Senior Affairs |
Precigen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Precigen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.68 | ||||
| Return On Asset | -0.67 | ||||
| Operating Margin | (32.54) % | ||||
| Current Valuation | 1.72 B | ||||
| Shares Outstanding | 352.91 M | ||||
| Shares Owned By Insiders | 13.73 % | ||||
| Shares Owned By Institutions | 63.48 % | ||||
| Number Of Shares Shorted | 41.98 M | ||||
| Price To Earning | (2.06) X | ||||
| Price To Book | 41.75 X |
Pair Trading with Precigen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Precigen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Precigen will appreciate offsetting losses from the drop in the long position's value.Moving against Precigen Stock
| 0.63 | VCYT | Veracyte | PairCorr |
| 0.55 | DRMA | Dermata Therapeutics | PairCorr |
| 0.35 | OSE | OSE Pharma SA | PairCorr |
| 0.31 | RAC | Race Oncology Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Precigen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Precigen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Precigen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Precigen to buy it.
The correlation of Precigen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Precigen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Precigen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Precigen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Precigen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in discontinued. To learn how to invest in Precigen Stock, please use our How to Invest in Precigen guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Will Biotechnology sector continue expanding? Could Precigen diversify its offerings? Factors like these will boost the valuation of Precigen. Anticipated expansion of Precigen directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Precigen data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.41) | Revenue Per Share | Quarterly Revenue Growth 0.194 | Return On Assets | Return On Equity |
Investors evaluate Precigen using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Precigen's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Precigen's market price to deviate significantly from intrinsic value.
It's important to distinguish between Precigen's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Precigen should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Precigen's market price signifies the transaction level at which participants voluntarily complete trades.